Issuu on Google+

Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017 Anxiety Disorders Therapeutics Market is Forecast to Show Steady Growth until 2017 GlobalData estimates that the global anxiety disorders therapeutics market was valued at $3,698m inn 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 6.3% over the next seven years, to reach $5,689m by 2017. This steady growth is primarily attributed to only one product launch for generalized anxiety disorder, disease awareness and alternate treatment options other than pharmacotherapy. GlobalData’s research indicates that the current market is well served by FDA (Food and Drug Administration)-approved drugs, off label drugs and alternative therapies such as cognitive behavioral therapy. Patients with the symptoms of anxiety disorders tend to depend more on alternative therapies such as cognitive behavioral therapy instead of medication. The current treatment options have moderate safety and efficacy. This indicates that the anxiety disorders therapeutics market has treatment options which are currently satisfying patients but that the treatment rates and awareness of anxiety disorders is low. GlobalData found that there are 54 products in the different stages of development. Lu AA21004, currently in Phase III, is the most promising products in the late stage pipeline. Drugs in the pipeline have shown encouraging response rates in pretreated patients and have great potential in the anxiety disorders therapeutics market. The pipeline candidates are mainly concentrated in Phase II of clinical development. These products are expected to meet some of the unmet needs of the market. They may also lead to an intensely competitive market. In summary, the global anxiety disorders therapeutics market is heading towards a highly competitive landscape. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=AnxietyDisorders-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017 The anxiety disorders therapeutics market has moderate unmet needs. This is due to lack of awareness among physicians and patients, and low diagnosis and treatment rates. The anxiety disorders therapeutics market has many FDA-approved therapies available for treatment. The therapies which are available for the treatment of anxiety have shown moderate efficacy and safety profiles, which lead to moderate unmet need. The market is wide open for novel entrants to fulfill the unmet need of the anxiety disorders therapeutics market. GlobalData, the industry analysis specialist, has released its new report, “Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017�. The report is an essential source of information and analysis on the global anxiety disorders market. The report identifies the key trends shaping and driving the global anxiety disorders market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current


market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global anxiety disorders sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Anxiety-Disorders-TherapeuticsPipeline-Assessment-and-Market-Forecasts-to-2017 Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782


Anxiety Disorders Therapeutics - Pipeline Assessment and Market Forecasts to 2017